drugset / Trial / NCT05959447
Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 1, 2-part, open-label, fixed-sequence study evaluating potential drug-drug interactions between gemfibrozil (part 1) or dabigatran etexilate (part 2) and camlipixant (BLU-5937) 50 mg tablet in healthy participants under fasting conditions.
Timeline
- Start
- 2023-07-26
- Primary completion
- 2023-10-13
- Completion
- 2023-10-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camlipixant | Small molecule | 50 mg | Oral |
| Subject | Dabigatran etexilate | Unknown | 150 mg | Oral |
| Subject | Gemfibrozil | Small molecule | 600 mg | Oral |
Indications
No indication recorded.